作为癌症治疗点的c-Kit受体:当前的见解
Mona S Abdellateif1, Ahmed K Bayoumi2,3, Mohammed Aly Mohammed1
1Medical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11796, Egypt.
OncoTargets and therapy
|October 4, 2023
概括
c-Kit受体氨酸激酶 (RTK) 异常驱动各种癌症. 氨酸激酶抑制剂 (TKIs) 对治疗c-KIT突变瘤有希望,但精确的突变检测对于个性化治疗至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- c-Kit是一种III型受体氨酸激酶 (RTK),调节细胞存活和细胞亡等关键生物过程.
- 在c-KIT中的异常,包括过度表达和突变,与许多癌症的发展有关,如胃肠道瘤和急性髓性白血病.
- 在癌症发病过程中c-KIT的关键作用使其成为治疗干预的重要分子标.
研究的目的:
- 审查关于c-KIT突变在各种癌症中的作用的文献.
- 探索氨酸激酶抑制剂 (TKI) 在治疗具有c-KIT异常的癌症方面的潜力.
- 提供关于c-KIT作为个性化癌症治疗的治疗目标的见解.
主要方法:
- 对研究c-KIT突变及其在癌症中的作用的文献综述.
- 对氨酸激酶抑制剂 (TKI) 在治疗c-KIT驱动的恶性瘤方面的疗效研究的分析.
- 综合发现,以评估c-KIT作为分子标.
主要成果:
- c-KIT突变与多种癌症的发病有关,包括胃肠道瘤,巨细胞瘤,急性髓性白血病,乳腺癌,甲状腺癌和结直肠癌.
- 氨酸激酶抑制剂 (TKI) 是一种有前途的治疗策略,用于患有c-KIT异常的癌症.
- 技术技能的有效性取决于存在的特定类型的c-KIT突变.
结论:
- c-KIT在各种癌症类型中发挥着重要作用,使其成为一个可行的分子标.
- 针对c-KIT的个性化治疗需要准确检测特定的潜在突变.
- 在患有c-KIT异常的患者中,TKIs为有效的癌症治疗提供了潜在的途径,这强调了有针对性的方法的重要性.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.8K
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
840
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:15M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:27Cytotoxic T Cells-mediated Immune Response
956
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
956